查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1972095

心臟瓣膜牽開器市場：按產品類型、應用和最終用戶分類－2026-2032年全球預測

Cardiac Valvulotome Market by Product Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，心臟瓣膜牽開器市場價值將達到 1.3318 億美元，到 2026 年將成長至 1.4689 億美元，到 2032 年將達到 1.9764 億美元，複合年成長率為 5.80%。

主要市場統計數據
基準年 2025 1.3318億美元
預計年份：2026年 1.4689億美元
預測年份 2032 1.9764億美元
複合年成長率 (%) 5.80%

基於資訊的心臟瓣膜牽開器引入：臨床背景、設備發展歷程以及影響引入和採購決策的因素。

瓣膜牽開器是一種用於治療瓣膜性心臟病的專用器械，可透過微創或外科手術進行，其應用範圍涵蓋主動脈瓣、二尖瓣、肺動脈瓣和三尖瓣的介入治療。隨著人們越來越重視縮短手術時間、降低併發症發生率和改善病患復健情況，臨床對精密器械的需求日益成長。因此，器械設計不斷發展，更加重視人體工學、採用先進材料以及與混合手術室的兼容性，使臨床醫生能夠將瓣膜牽開器整合到各種治療方案中。

重塑心臟瓣膜切牙領域的關鍵變革因素是技術創新、醫療保健環境的變化以及不斷變化的監管和報銷重點。

由於技術進步、醫療實踐的演變以及臨床醫生對能夠提高手術精準度的器械日益成長的需求，心臟瓣膜牽開器的市場格局正在經歷一場變革。小型化和材料科學的進步使得器械的截面尺寸更小、耐用性更高，並且能夠實現創傷更小、可重複的手術操作，從而更好地適應臨床路徑。因此，能夠與先進影像設備和混合手術環境配合使用的器械，正日益受到尋求更高控制力和更可預測手術結果的外科團隊的青睞。

分析美國在 2025 年實施的關稅政策對醫療設備相關人員的供應鏈韌性、採購重點和製造決策的累積影響。

美國於2025年實施的政策措施對整個醫療設備供應鏈產生了累積影響，波及製造、籌資策略和醫院採購等各個環節。關稅調整和貿易政策的變化影響了零件和成品的成本結構，迫使製造商重新評估與供應商的關係、國內生產的可能性以及庫存緩衝方法，以維持供應的連續性並緩解成本波動。

實際的細分分析揭示了應用特殊性、最終用戶環境以及一次性產品和可重複使用產品之間的選擇如何驅動商業化和臨床引入策略。

細分市場層面的洞察揭示了跨臨床應用領域、醫療環境和產品原型的專業知識如何影響創新重點和商業化策略。主動脈瓣、二尖瓣、肺動脈瓣和三尖瓣疾病需要介入治療的患者，需要使用根據解剖特徵和細微手術差異量身定做的器械。為此，器械設計團隊最佳化了葉片形狀、軸桿柔軟性以及與輔助器械的兼容性，以滿足這些多樣化的應用需求。因此，臨床證據的產生通常按瓣膜類型分層，以證明每種解剖類型族群的療效和安全性。

區域策略考量：強調醫療服務模式、監管多樣性和供應現實如何對世界不同地區的實施產生不同的影響。

區域績效模式反映了美洲、歐洲、中東和非洲以及亞太地區在醫療服務模式、法規環境和投資重點方面的差異。在美洲，綜合醫療系統和專科心臟中心的集中發展推動了對支持高治療能力、能夠與先進影像設備和混合手術室整合的醫療設備的需求。臨床醫生網路和當地意見領袖在塑造新設備的推廣應用路徑和檢驗其有效性方面發揮著至關重要的作用。

產業競爭動態揭示了產品差異化、臨床夥伴關係和供應策略如何決定臨床醫生的長期定位和採用。

心臟瓣膜切除器材領域的競爭格局取決於產品改進的漸進式策略、策略聯盟以及對臨床證據的定向投資。領先的研發企業致力於提升器材的人體工學設計、增強與影像系統的相容性，並拓展消毒流程的適應性。與臨床中心建立合作關係以及參與研究者主導的臨床研究，有助於提升市場信譽並提高外科醫生的手術技能；同時，服務和培訓計畫也逐漸成為促進器械應用之外的差異化因素。

為製造商和醫療保健系統提供切實可行的優先建議，以加快採用速度、增強供應鏈韌性，並使商業模式與臨床工作流程保持一致。

產業領導者應推動制定協調一致的策略，整合產品創新、臨床工作流程最佳化、法規遵循規劃和供應鏈韌性。優先採用模組化設計原則，使器械能夠根據主動脈瓣、二尖瓣、肺動脈瓣和三尖瓣的特定需求進行調整，這將減輕臨床醫生的負擔，並有助於產生有針對性的循證醫學證據。同時，投資於全面的培訓計畫和指導，將增強臨床醫生的信心，並縮短他們掌握新器械所需的時間。

結合臨床醫師的訪談、監管審查和供應鏈分析的嚴謹混合調查方法，可得出經過驗證的實用見解。

本報告的研究採用了一種混合方法，將定性一手研究與有針對性的二手資訊分析相結合，以獲得精準且實用的見解。一手研究包括對心臟外科醫生、採購負責人、臨床技術人員和監管專家進行結構化訪談，以收集關於器械性能、採購標準和實施挑戰的第一手觀點。這些訪談內容與器械標籤材料、監管申報文件、同行評審的臨床文獻和技術白皮書相結合，建構出檢驗的、基於臨床和監管背景的見解。

將設備創新、營運準備和供應保障與永續的臨床部署和市場韌性聯繫起來的策略結論進行簡潔整合。

心臟瓣膜切除器材市場正處於轉折點，器械的改進、醫療環境的變化以及政策的調整相互交織，為製造商和醫療系統帶來了機會和挑戰。器械團隊若能根據主動脈瓣、二尖瓣、肺動脈瓣和三尖瓣每種介入治療的解剖學特徵設計器械，並針對各醫療機構（例如門診手術中心、心臟中心、醫院和專科診所）的實際情況提供量身定做的支持，便能將臨床研究成果轉化為常規應用。同時，積極主動的供應鏈策略以及與醫療機構採購負責人的透明協作至關重要，有助於克服採購流程的複雜性，並應對關稅造成的供應波動。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：心臟瓣膜牽開器市場：依產品類型分類

  • 一次性
  • 可重複使用的

第9章：心臟瓣膜牽開器市場：依應用領域分類

  • 主動脈瓣
  • 二尖瓣
  • 肺動脈瓣
  • 三尖瓣

第10章：心臟瓣膜牽開器市場：依最終用戶分類

  • 門診手術中心
  • 心臟中心
  • 醫院
  • 專科診所

第11章：心臟瓣膜牽開器市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章：心臟瓣膜牽開器市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：心臟瓣膜牽開器市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國心臟瓣膜牽開器市場

第15章：中國心臟瓣膜牽開器市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Andramed GmbH
  • B. Braun Melsungen AG
  • Boston Scientific Corporation
  • Cardinal Health, Inc.
  • Cook Medical LLC
  • Edwards Lifesciences Corporation
  • Koven Technology Canada Inc.
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • Symmetry Surgical Inc
  • Teleflex Incorporated
  • Terumo Corporation
Product Code: MRR-2B5802CFEB49

The Cardiac Valvulotome Market was valued at USD 133.18 million in 2025 and is projected to grow to USD 146.89 million in 2026, with a CAGR of 5.80%, reaching USD 197.64 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 133.18 million
Estimated Year [2026] USD 146.89 million
Forecast Year [2032] USD 197.64 million
CAGR (%) 5.80%

An informed introduction to cardiac valvulotomes outlining clinical context, device evolution, and factors that influence adoption and procurement decisions

Cardiac valvulotomes are specialized instruments used in procedures to address valvular pathologies through minimally invasive or surgical approaches, and their relevance spans aortic, mitral, pulmonary, and tricuspid interventions. Clinical demand for precision tools has grown alongside an emphasis on shorter procedural times, reduced complication rates, and improved patient recovery profiles. Consequently, device design has evolved to prioritize ergonomics, cutting-edge materials, and compatibility with hybrid procedural suites, allowing clinicians to integrate valvulotomes within varied care pathways.

Technological advances have improved device tip design, visualization compatibility, and single-use sterility options, thereby influencing purchasing decisions across ambulatory surgery centers, cardiac centers, hospitals, and specialty clinics. As clinicians and procurement teams seek instruments that harmonize reliability with cost-effectiveness, the interplay between disposable and reusable product models becomes a focal point in deliberations. Transitioning from legacy devices to next-generation valvulotomes requires coordinated clinical validation, inventory management adjustments, and training initiatives to ensure safe, effective adoption.

Looking ahead, the intersection of procedural innovation, clinician preferences, and institutional purchasing priorities will determine adoption trajectories, with regulatory clarity and health-economic rationales serving as pivotal enablers for broader clinical uptake.

Key transformative forces reshaping the cardiac valvulotome landscape driven by technology, care setting migration, and evolving regulatory and reimbursement priorities

The landscape for cardiac valvulotomes is undergoing transformative shifts driven by technological refinement, evolving care settings, and rising clinician expectations for instruments that enhance procedural precision. Miniaturization and materials science breakthroughs have reduced cross-sectional profiles while improving durability, enabling interventions that are less invasive and better suited to repeatable clinical pathways. As a result, devices that integrate with advanced imaging modalities and hybrid operating environments are increasingly prioritized by surgical teams seeking greater control and predictable outcomes.

Simultaneously, the redistribution of cardiac services into ambulatory environments and specialty clinics is reshaping purchasing dynamics and inventory models. These changes prompt manufacturers to offer product portfolios that accommodate both single-use convenience and reusable cost efficiencies, along with targeted training and warranty structures. Regulatory and reimbursement frameworks are also adapting, with authorities emphasizing post-market surveillance and real-world evidence to validate safety and performance claims.

Taken together, these shifts create new imperatives for manufacturers, clinicians, and health systems to collaborate on clinical validation, workflow integration, and value communication. In this dynamic context, organizations that align innovation with pragmatic adoption support will secure stronger clinical endorsements and long-term integration into procedural standards.

An analysis of how 2025 United States tariff developments have cumulatively reshaped supply chain resilience, procurement priorities, and manufacturing decisions for device stakeholders

Policy measures enacted in the United States in 2025 have exerted cumulative effects across medical device supply chains, with implications for manufacturing, sourcing strategies, and hospital procurement. Tariff adjustments and trade policy shifts influenced the cost structures of components and finished devices, prompting manufacturers to reassess supplier relationships, onshore manufacturing potential, and inventory buffering practices to preserve continuity of supply and mitigate cost volatility.

As a result, procurement teams have increasingly emphasized supply chain resilience and supplier diversification. Hospitals and surgical centers now factor total landed cost and lead-time reliability into purchasing decisions more prominently than before, and device developers face heightened scrutiny regarding component provenance and manufacturing traceability. Moreover, the administrative burden associated with customs compliance and cross-border logistics has led some organizations to favor simplified device portfolios and to accelerate qualification of local suppliers.

In parallel, regulatory bodies and institutional contracting teams have sought greater transparency around unit cost drivers and lifecycle expenses. Consequently, manufacturers that proactively disclose supply chain strategies, offer flexible distribution models, and engage in collaborative contracting have preserved competitive positioning. Looking forward, these dynamics underscore the strategic importance of operational agility, predictable supply commitments, and clear communication with clinical and procurement stakeholders.

Actionable segmentation insights revealing how application specificity, end-user environment, and disposable versus reusable choices drive commercialization and clinical adoption strategies

Segment-level insights reveal how specialization by clinical application, care settings, and product archetypes informs both innovation priorities and commercialization strategies. Patients presenting with conditions requiring aortic, mitral, pulmonary, or tricuspid interventions demand instruments tailored to anatomical and procedural nuances, and device design teams have responded by optimizing blade geometry, shaft flexibility, and compatibility with adjunct devices to address these distinct application needs. Consequently, clinical evidence generation is often stratified by valve type to demonstrate efficacy and safety within each anatomic cohort.

End-user dynamics further influence product positioning. Ambulatory surgery centers, cardiac centers, hospitals, and specialty clinics exhibit different capital structures, procurement cycles, and inventory capacities, so manufacturers must calibrate pricing, service agreements, and training offerings to fit each setting. For example, ambulatory environments often prioritize rapid turnover and single-use convenience, whereas larger hospitals may assess total lifecycle costs and favor reusable systems that align with sterilization workflows. Product-type decisions therefore hinge on the trade-offs between disposability benefits, including infection control and simplified logistics, and reusable advantages such as lower per-procedure cost when sterilization workflows are optimized.

In sum, a thoughtful segmentation-driven approach to clinical validation, commercialization, and post-market support enables more precise alignment between device capabilities and the operational realities of diverse clinical environments.

Regional strategic observations emphasising how healthcare delivery models, regulatory diversity, and supply realities differently influence adoption across global territories

Regional performance patterns reflect distinct healthcare delivery models, regulatory environments, and investment priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, integrated health systems and a concentration of specialized cardiac centers have driven demand for devices that support high procedural throughput and integration with advanced imaging and hybrid suites. Clinician networks and regional opinion leaders play an outsized role in shaping adoption pathways and in validating new device entrants.

Across Europe, Middle East & Africa, procurement pathways and reimbursement policies vary substantially, prompting manufacturers to adopt differentiated market entry strategies and to invest in robust clinical evidence generation that satisfies diverse regulatory expectations. Regional distributors and local clinical champions are pivotal for navigating complex public and private payer landscapes. In the Asia-Pacific region, rapid healthcare infrastructure development in some markets has increased demand for scalable device solutions and for manufacturing partnerships that localize supply and reduce time to market.

Across all regions, interoperability with existing systems, training investments, and supply chain reliability remain universal priorities. Therefore, organizations that tailor toolkit bundles, education programs, and distribution models to regional nuances increase their probability of long-term adoption and better alignment with institutional priorities.

Industry competitive dynamics showing how product differentiation, clinical partnerships, and supply strategies determine long-term positioning and clinician uptake

Competitive dynamics in the cardiac valvulotome domain are defined by a combination of incremental product improvements, strategic collaborations, and targeted investments in clinical evidence. Leading developers have concentrated on refining device ergonomics, compatibility with imaging systems, and options that address sterilization workflows. Partnerships with clinical centers and participation in investigator-initiated studies have strengthened market credibility and facilitated surgeon familiarity, while service and training programs have emerged as differentiating offerings that support adoption beyond the device itself.

In addition, supply chain strategies and manufacturing footprints are increasingly strategic levers. Companies that demonstrate transparent sourcing practices and offer flexible distribution or consignment models find alignment with hospital procurement teams that prioritize supply certainty. Intellectual property and regulatory compliance investments remain critical for defending competitive positions, and M&A activity continues to be a tactical route for acquiring niche technologies or scaling distribution capacity rapidly.

In this environment, companies that balance technical differentiation with pragmatic adoption support-such as hands-on training, robust post-market surveillance, and responsive customer service-are better placed to secure clinician trust and to integrate their products into routine procedural algorithms.

Practical and prioritized recommendations for manufacturers and health systems to accelerate adoption, strengthen supply resilience, and align commercial models with clinical workflows

Industry leaders should pursue a coordinated strategy that aligns product innovation with clinical workflow optimization, regulatory planning, and supply chain resilience. Prioritizing modular design principles that allow device variants to address aortic, mitral, pulmonary, and tricuspid needs reduces complexity for clinicians while enabling targeted evidence generation. Concurrently, investing in comprehensive training programs and proctoring builds clinician confidence and shortens the learning curve for new devices.

Procurement-focused initiatives should emphasize transparent lifecycle cost analyses, flexible contracting options, and localized distribution arrangements to reduce exposure to tariff-driven cost fluctuations and logistic delays. Manufacturers can also mitigate risk by diversifying supplier networks and by qualifying alternative manufacturing sites to shorten lead times. To accelerate market acceptance, companies should partner with high-volume clinical centers to develop real-world evidence and to publish outcomes that resonate with both clinicians and payers.

Finally, establishing robust post-market surveillance and feedback loops enables continuous product improvement and strengthens regulatory dossiers. By integrating clinical, operational, and commercial strategies, industry leaders can convert innovation into sustainable adoption and position their organizations to respond quickly to evolving clinical and policy environments.

A rigorous mixed-methods research approach combining clinician interviews, regulatory review, and supply chain mapping to produce validated practical insights

The research underpinning this report employed a mixed-methods approach combining primary qualitative engagement with targeted secondary source analysis to produce nuanced, actionable insights. Primary inputs included structured interviews with cardiac surgeons, procurement officers, clinical engineers, and regulatory specialists to capture frontline perspectives on device performance, purchasing considerations, and implementation challenges. These conversations were synthesized with device labeling, regulatory filings, peer-reviewed clinical literature, and technical white papers to ground findings in verifiable clinical and regulatory context.

Analytical methods included thematic coding of interview data to identify recurring adoption barriers and enablers, crosswalks between procedural workflows and device features, and supply chain mapping to assess exposure to logistics and tariff pressures. Quality assurance measures included triangulation of primary inputs with independent secondary sources and iterative validation of findings through expert review panels. Wherever possible, comparisons across clinical settings and geographic regions were drawn to ensure the conclusions reflect diverse operational realities.

This methodology balances depth of clinician insight with breadth of secondary validation to provide practitioners and decision-makers with pragmatic guidance that is rooted in observed practice patterns and regulatory frameworks.

A concise synthesis of strategic conclusions tying device innovation, operational readiness, and supply assurance to sustainable clinical adoption and market resilience

The cardiac valvulotome landscape is at an inflection point where device refinement, changing care settings, and policy shifts intersect to create both opportunities and challenges for manufacturers and health systems. Device teams that align design with the anatomical specificity of aortic, mitral, pulmonary, and tricuspid interventions, and that tailor support to the operational realities of ambulatory surgery centers, cardiac centers, hospitals, and specialty clinics, will be better prepared to convert clinical interest into routine use. Simultaneously, navigating procurement complexities and responding to tariff-driven supply dynamics require proactive supply chain strategies and transparent engagement with institutional buyers.

Ultimately, success will hinge on delivering demonstrable clinical value, ensuring logistic reliability, and providing robust training and post-market support. Stakeholders who build partnerships across clinical, operational, and regulatory domains will not only accelerate adoption but also create resilient pathways for sustained clinical impact. The next phase of market evolution will reward those that execute on multi-dimensional strategies that balance innovation with pragmatic, evidence-based adoption plans.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiac Valvulotome Market, by Product Type

  • 8.1. Disposable
  • 8.2. Reusable

9. Cardiac Valvulotome Market, by Application

  • 9.1. Aortic
  • 9.2. Mitral
  • 9.3. Pulmonary
  • 9.4. Tricuspid

10. Cardiac Valvulotome Market, by End User

  • 10.1. Ambulatory Surgery Centers
  • 10.2. Cardiac Centers
  • 10.3. Hospitals
  • 10.4. Specialty Clinics

11. Cardiac Valvulotome Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Cardiac Valvulotome Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Cardiac Valvulotome Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Cardiac Valvulotome Market

15. China Cardiac Valvulotome Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Abbott Laboratories
  • 16.6. Andramed GmbH
  • 16.7. B. Braun Melsungen AG
  • 16.8. Boston Scientific Corporation
  • 16.9. Cardinal Health, Inc.
  • 16.10. Cook Medical LLC
  • 16.11. Edwards Lifesciences Corporation
  • 16.12. Koven Technology Canada Inc.
  • 16.13. Medtronic plc
  • 16.14. Merit Medical Systems, Inc.
  • 16.15. Symmetry Surgical Inc
  • 16.16. Teleflex Incorporated
  • 16.17. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARDIAC VALVULOTOME MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CARDIAC VALVULOTOME MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES CARDIAC VALVULOTOME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA CARDIAC VALVULOTOME MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY DISPOSABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY DISPOSABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY DISPOSABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY REUSABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY REUSABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY REUSABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY AORTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY AORTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY AORTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY MITRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY MITRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY MITRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY PULMONARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY PULMONARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY PULMONARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY TRICUSPID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY TRICUSPID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY TRICUSPID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. AMERICAS CARDIAC VALVULOTOME MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 37. AMERICAS CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 38. AMERICAS CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 39. AMERICAS CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. NORTH AMERICA CARDIAC VALVULOTOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. NORTH AMERICA CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 42. NORTH AMERICA CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 43. NORTH AMERICA CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 44. LATIN AMERICA CARDIAC VALVULOTOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. LATIN AMERICA CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. LATIN AMERICA CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 47. LATIN AMERICA CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 48. EUROPE, MIDDLE EAST & AFRICA CARDIAC VALVULOTOME MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 49. EUROPE, MIDDLE EAST & AFRICA CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. EUROPE, MIDDLE EAST & AFRICA CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 51. EUROPE, MIDDLE EAST & AFRICA CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. EUROPE CARDIAC VALVULOTOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. EUROPE CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. EUROPE CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. MIDDLE EAST CARDIAC VALVULOTOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. MIDDLE EAST CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. MIDDLE EAST CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 59. MIDDLE EAST CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. AFRICA CARDIAC VALVULOTOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. AFRICA CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. AFRICA CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. AFRICA CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC CARDIAC VALVULOTOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. ASEAN CARDIAC VALVULOTOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. ASEAN CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. ASEAN CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. ASEAN CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. GCC CARDIAC VALVULOTOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GCC CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. GCC CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. GCC CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPEAN UNION CARDIAC VALVULOTOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPEAN UNION CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPEAN UNION CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPEAN UNION CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. BRICS CARDIAC VALVULOTOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. BRICS CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. BRICS CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. BRICS CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. G7 CARDIAC VALVULOTOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. G7 CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. G7 CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. G7 CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. NATO CARDIAC VALVULOTOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. NATO CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. NATO CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. NATO CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CARDIAC VALVULOTOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. UNITED STATES CARDIAC VALVULOTOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 95. UNITED STATES CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. UNITED STATES CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. UNITED STATES CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. CHINA CARDIAC VALVULOTOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 99. CHINA CARDIAC VALVULOTOME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. CHINA CARDIAC VALVULOTOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. CHINA CARDIAC VALVULOTOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)